ASH 2023 preview – Syndax gets an edge on Kura

In the menin inhibitor approval race Syndax had already pulled ahead of its main competitor, Kura Oncology. Now Syndax has got one up on its rival again, today unveiling a late-breaking abstract at the upcoming ASH meeting for its contender, revumenib. Kura won't have a major presence at ASH, and before today’s announcement it had looked like the main representative of menin inhibition would be Johnson & Johnson, with early – and so far not very impressive – results on JNJ-75276617. Syndax’s ASH presentation will concern data from the pivotal portion of the Augment-101 trial of revumenib in relapsed/refractory KMT2A-rearranged leukaemia. The results in the abstract are the same as the company reported in October; presumably these will be updated at ASH. Syndax plans to complete its ongoing revumenib filing in KMT2Ar acute leukaemia by year-end; it also previously promised an update in 2024 in NPM1 mutants, the other main genetic subtype in which it is testing revumenib. In an earlier ASH coup, Syndax and Incyte’s axatilimab bagged a spot at the plenary session, with the Agave-201 trial in chronic graft-versus-host disease.

Selected Syndax ASH abstracts

Source: ASH & OncologyPipeline.

This story has been updated to remove mention of Syndax's share price move.